Somewhat Favorable Media Coverage Somewhat Unlikely to Impact ACADIA Pharmaceuticals (ACAD) Share Price

Media headlines about ACADIA Pharmaceuticals (NASDAQ:ACAD) have trended somewhat positive on Thursday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.5419817916781 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

ACADIA Pharmaceuticals (ACAD) traded up $0.38 during midday trading on Thursday, hitting $30.09. The company had a trading volume of 906,055 shares, compared to its average volume of 1,657,414. ACADIA Pharmaceuticals has a one year low of $24.31 and a one year high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The company had revenue of $35.58 million for the quarter, compared to analyst estimates of $32.03 million. During the same period in the previous year, the company posted ($0.61) earnings per share. The firm’s revenue was up 571.3% on a year-over-year basis. research analysts predict that ACADIA Pharmaceuticals will post -2.41 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Wednesday, November 15th. ValuEngine lowered ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, November 8th. Cowen reiterated a “buy” rating and issued a $46.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Tuesday, November 7th. Finally, Jefferies Group reiterated a “buy” rating and issued a $47.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $47.44.

In related news, EVP Glenn Baity sold 37,500 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $40.91, for a total transaction of $1,534,125.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 22.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/08/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-acadia-pharmaceuticals-acad-share-price.html.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply